文献リスト

1) Ekenel M, Deangelis LM. Treatment of primary central nervous system lymphoma. Curr Treat Options Neurol. 2007; 9: 271-82

2) Deckert M, Engert A, Brück W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011 Aug 5. doi: 10. 1038/leu. 2011. 169. [Epub ahead of print]

3) Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005; 62: 1595-600

4) Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol. 2009; 8: 581-92

5) Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998; 16: 859-63

6) Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 1994; 81: 188-95

7) Ferreri AJ, Reni M, Foppoli M, et al. International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose metho-trexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a random-ised phase 2 trial. Lancet. 2009; 374: 1512-20

8) Batchelor T, Carson K, OʼNeill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003; 21: 1044-9

9) Herrlinger U, Küker W, Uhl M, et al. Neuro-Oncology Working Group of the German Society. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol. 2005; 57: 843-7

10) Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006; 24: 4570-4

11) DeAngelis LM, Seiferheld W, Schold SC, et al. Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002; 20: 4643-8

12) Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. European Organization for Research and Treatment of Cancer Lymphoma Group. High-dose methotrexate-based chemo-therapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003; 21: 4483-8

13) Ferreri AJ, DellʼOro S, Foppoli M, et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lym-phomas. Neurology. 2006; 66: 1435-8

14) Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002; 58: 1513-20

15) Reni M, Ferreri AJ, Guha-Thakurta N, et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys. 2001; 51: 419-25

16) Ferreri AJ, Licata G, Foppoli M, et al. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. Oncologist. 2011; 16: 336-41

17) Gerstner ER, Carson KA, Grossman SA, et al. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology. 2008; 70: 401-2

18) Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003; 21: 4489-95

19) Pels H, Juergens A, Glasmacher A, et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intra-ventricular treatment: results of a phase II study. J Neurooncol. 2009; 91: 299-305

20) Angelov L, Doolittle ND, Kraemer DF, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol. 2009; 27: 3503-9

21) Hoang-Xuan K, Taillandier L, Chinot O, et al. European Organization for Research and Treat-ment of Cancer Brain Tumor Group. Chemo-therapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003; 21: 2726-31

22) Omuro AM, Taillandier L, Chinot O, et al. C Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol. 2007; 85: 207-11

23) Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lympho-mas. Br J Cancer. 2007; 96: 864-7

24) Enting RH, Demopoulos A, DeAngelis LM, et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology. 2004; 63: 901-3

25) Fischer L, Thiel E, Klasen HA, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006; 17: 1141-5

26) Batchelor TT, Grossman SA, Mikkelsen T, et al. Rituximab monotherapy for patients with recur-rent primary CNS lymphoma. Neurology. 2011; 76: 929-30

27) Chamberlain MC, Johnston SK. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol. 2010 Feb 8. [Epub ahead of print]

28) Maza S, Kiewe P, Munz DL, et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol. 2009; 11: 423-9

29) Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radio-therapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010; 11: 1036-47

30) James L, Rubenstein, Jeffrey L, et al. Intensive chemotherapy and immunotherapy, without brain irradiation, in newly diagnosed patients with primary CNS Lymphoma: Results of CALGB 50202 Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 763

31) Omuro A, Taillandier L, Chinot O, et al. ANOCEF Group (French Neuro-Oncology Association). Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred？ J Neurooncol. 2011; 104: 323-30

32) Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007; 25: 4730-5

33) Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemo-therapy and reduced-dose radiotherapy. J Neurooncol. 2009; 91: 315-21

34) Ferreri AJ, Verona C, Politi LS, et al. Consoli-dation radiotherapy in primary central nervous system lymphomas: impact on outcome of differ-ent fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys. 2011; 80: 169-75

35) Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol. 2007; 18: 1145-51

36) Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hemato-poietic stem-cell rescue for refractory and recur-rent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008; 26: 2512-8

37) Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell trans-plantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006; 24: 3865-70

38) Illerhaus G, Muller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008; 93: 147-8

39) Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005; 23: 1507-13

40) Hottinger AF, DeAngelis LM, Yahalom J, et al. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology. 2007; 69: 1178-82

41) Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004; 10: 5643-6

42) Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011; 118: 510-22

43) Widemann BC, Balis FM, Kim A, et al. Glucar-pidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol. 2010; 28: 3979-86

44) Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000; 18: 3144-50

45) OʼBrien P, Roos D, Pratt G, et al. Phase II multi-center study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000; 18: 519-26

46) Bessell EM, Lopez-Guillermo A, Villa S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analy-sis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol. 2002; 20: 231-6

47) Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009; 11: 211-5

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp